Meiji Yasuda Asset Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $624K | Buy |
2,943
+621
| +27% | +$122K | 0.03% | 336 |
|
|
2026
Q1 | $455K | Sell |
2,322
-15
| -0.6% | -$2.91K | 0.02% | 357 |
|
|
2025
Q4 | $406K | Hold |
2,337
| – | – | 0.02% | 372 |
|
|
2025
Q3 | $445K | Sell |
2,337
-181
| -7% | -$32.1K | 0.02% | 356 |
|
|
2025
Q2 | $452K | Sell |
2,518
-1,325
| -34% | -$230K | 0.02% | 356 |
|
|
2025
Q1 | $650K | Hold |
3,843
| – | – | 0.03% | 379 |
|
|
2024
Q4 | $580K | Buy |
3,843
+60
| +2% | +$9.33K | 0.02% | 407 |
|
|
2024
Q3 | $587K | Sell |
3,783
-20
| -0.5% | -$2.99K | 0.02% | 409 |
|
|
2024
Q2 | $521K | Sell |
3,803
-393
| -9% | -$53.8K | 0.02% | 421 |
|
|
2024
Q1 | $559K | Sell |
4,196
-4,256
| -50% | -$552K | 0.02% | 407 |
|
|
2023
Q4 | $1.17M | Buy |
8,452
+90
| +1% | +$11.8K | 0.05% | 296 |
|
|
2023
Q3 | $1.02M | Buy |
8,362
+3,910
| +88% | +$521K | 0.05% | 319 |
|
|
2023
Q2 | $626K | Sell |
4,452
-50
| -1% | -$6.89K | 0.03% | 357 |
|
|
2023
Q1 | $637K | Sell |
4,502
-4,856
| -52% | -$695K | 0.03% | 355 |
|
|
2022
Q4 | $1.46K | Buy |
9,358
+10
| +0.1% | +$1.44K | 0.07% | 270 |
|
|
2022
Q3 | $1.15M | Sell |
9,348
-130
| -1% | -$17.1K | 0.07% | 287 |
|
|
2022
Q2 | $1.26M | Buy |
9,478
+4,710
| +99% | +$642K | 0.07% | 279 |
|
|
2022
Q1 | $653K | Sell |
4,768
-40
| -0.8% | -$5.58K | 0.04% | 403 |
|
|
2021
Q4 | $832K | Sell |
4,808
-260
| -5% | -$39.6K | 0.05% | 298 |
|
|
2021
Q3 | $736K | Sell |
5,068
-201
| -4% | -$29.4K | 0.05% | 304 |
|
|
2021
Q2 | $695K | Buy |
5,269
+2,240
| +74% | +$293K | 0.03% | 321 |
|
|
2021
Q1 | $389K | Buy |
3,029
+741
| +32% | +$91.3K | 0.03% | 388 |
|
|
2020
Q4 | $273K | Sell |
2,288
-80
| -3% | -$9.75K | 0.03% | 352 |
|
|
2020
Q3 | $271K | Sell |
2,368
-1,000
| -30% | -$118K | 0.03% | 318 |
|
|
2020
Q2 | $384K | Buy |
+3,368
| New | +$357K | 0.04% | 338 |
|
|
2020
Q1 | – | Sell |
-4,608
| Closed | -$492K | – | 345 |
|
|
2019
Q4 | $492K | Sell |
4,608
-3,600
| -44% | -$375K | 0.04% | 331 |
|
|
2019
Q3 | $879K | Buy |
8,208
+500
| +6% | +$51.3K | 0.07% | 277 |
|
|
2019
Q2 | $785K | Sell |
7,708
-410
| -5% | -$39.4K | 0.07% | 296 |
|
|
2019
Q1 | $730K | Sell |
8,118
-3,800
| -32% | -$329K | 0.06% | 296 |
|
|
2018
Q4 | $992K | Buy |
11,918
+3,800
| +47% | +$356K | 0.09% | 231 |
|
|
2018
Q3 | $876K | Buy |
8,118
+320
| +4% | +$35.1K | 0.07% | 271 |
|
|
2018
Q2 | $857K | Hold |
7,798
| – | – | 0.08% | 271 |
|
|
2018
Q1 | $782K | Buy |
7,798
+280
| +4% | +$28.7K | 0.07% | 281 |
|
|
2017
Q4 | $740K | Hold |
7,518
| – | – | 0.07% | 291 |
|
|
2017
Q3 | $704K | Sell |
7,518
-170
| -2% | -$18K | 0.07% | 291 |
|
|
2017
Q2 | $855K | Sell |
7,688
-180
| -2% | -$19K | 0.09% | 246 |
|
|
2017
Q1 | $773K | Buy |
7,868
+130
| +2% | +$12.4K | 0.08% | 264 |
|
|
2016
Q4 | $711K | Buy |
7,738
+219
| +3% | +$18.9K | 0.08% | 268 |
|
|
2016
Q3 | $636K | Buy |
7,519
+2,350
| +45% | +$197K | 0.07% | 271 |
|
|
2016
Q2 | $421K | Buy |
+5,169
| New | +$394K | 0.06% | 302 |
|
|
2015
Q3 | – | Sell |
-2,819
| Closed | -$204K | – | 350 |
|
|
2015
Q2 | $204K | Buy |
+2,819
| New | +$208K | 0.05% | 343 |
|
|
2014
Q2 | – | Sell |
-4,049
| Closed | -$235K | – | 359 |
|
|
2014
Q1 | $235K | Buy |
4,049
+300
| +8% | +$16.1K | 0.05% | 320 |
|
|
2013
Q4 | $201K | Buy |
+3,749
| New | +$222K | 0.04% | 343 |
|
Other funds holding DGX
EIG
Meiji Yasuda Asset Management's DGX Position: Q2 2026 in Review
Meiji Yasuda Asset Management increased its Quest Diagnostics (DGX) stake by 27% in Q2 2026, buying an estimated $122K and bringing the position to 2,943 shares worth $624K. The position accounts for 0.03% of the portfolio, ranked #336.
Meiji Yasuda Asset Management first reported a position in DGX in Q4 2013 and has held it in 43 quarters since. The position peaked at $1.26M in Q2 2022. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Meiji Yasuda Asset Management held 2,943 shares of Quest Diagnostics worth $624K as of Q2 2026.
- Meiji Yasuda Asset Management bought 621 Quest Diagnostics shares in Q2 2026, an estimated $122K.
- Quest Diagnostics made up 0.03% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #336 holding.
- Meiji Yasuda Asset Management first reported a position in Quest Diagnostics in Q4 2013 and has held it in 43 quarters since.
- Meiji Yasuda Asset Management's Quest Diagnostics position peaked at $1.26M in Q2 2022.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.